Daraxonrasib Treatment in RAS-Mutated Pancreatic Cancer: Mechanisms, Clinical Evidence and Future Perspectives
DOI:
https://doi.org/10.62051/ndcdrx21Keywords:
Ductal adenocarcinoma; daraxonrasib; RAS-mutated pancreatic cancer.Abstract
Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies worldwide, with its poor prognosis stemming from aggressive progression, delayed detection, and limited treatment responses. While KRAS has attracted substantial interest as a therapeutic target, its molecular architecture long defied direct pharmacological intervention. The recent introduction of daraxonrasib (RMC-6236)—a multiselective RAS(ON) inhibitor capable of engaging multiple active RAS variants—marks a notable shift in this landscape. By targeting a broader range of mutations rather than a single subtype, this agent holds promise for treating a wider patient population. Preclinical investigations have demonstrated robust suppression of RAS signalling and notable tumour regression, while clinical studies have yielded encouraging patient outcomes. The Phase III RASolute 302 trial, in particular, reported substantial gains in overall survival, progression-free survival, and objective response rates relative to standard second-line chemotherapy. This review explores the pathogenic role of KRAS mutations in pancreatic cancer, traces the development and mechanism of daraxonrasib, evaluates supporting clinical data, and discusses its strengths, limitations, and future positioning in managing RAS-mutated PDAC.
Downloads
References
[1] J.P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf, D.H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives, Nat. Rev. Gastroenterol. Hepatol. 15 (2018) 333–348. https://doi.org/10.1038/s41575-018-0005-x.
[2] R.L. Siegel, T.B. Kratzer, A.N. Giaquinto, H. Sung, A. Jemal, Cancer statistics, 2025, CA Cancer J. Clin. 75 (2025) 10–45. https://doi.org/10.3322/caac.21871.
[3] M.B. Ryan, R.B. Corcoran, Therapeutic strategies to target RAS-mutant cancers, Nat. Rev. Clin. Oncol. 15 (2018) 709–720. https://doi.org/10.1038/s41571-018-0105-0.
[4] A.M. Waters, C.J. Der, KRAS: The critical driver and therapeutic target for pancreatic cancer, Cold Spring Harb. Perspect. Med. 8 (2018) a031435. https://doi.org/10.1101/cshperspect.a031435.
[5] M. Holderfield, B.J. Lee, J. Jiang, A. Tomlinson, K.J. Seamon, A. Mira, E. Patrucco, G. Goodhart, J. Dilly, Y. Gindin, N. Dinglasan, Y. Wang, L.P. Lai, S. Cai, L. Jiang, N. Nasholm, N. Shifrin, C. Blaj, H. Shah, M. Singh, Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy, Nature 629 (2024) 919–926. https://doi.org/10.1038/s41586-024-07205-6.
[6] E.M. O'Reilly, Z.A. Wainberg, A.E. Hendifar, M.J. Borad, F. Pietrantonio, S. Pant, P. Hammel, C. Cremolini, G.A. Manji, P.E. Oberstein, I. Garrido-Laguna, C. Springfeld, N.S. Azad, M. Ueno, S.Y. Chui, Y. Zhang, H. Patel, Y. Lee, Z. Salman, B.M. Wolpin, Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer, N. Engl. J. Med. (2026). https://doi.org/10.1056/NEJMoa2605555.
[7] J. Cregg, A.V. Edwards, S. Chang, B.J. Lee, J.E. Knox, A.C.A. Tomlinson, A. Marquez, Y. Liu, R. Freilich, N. Aay, Y. Wang, L. Jiang, J. Jiang, Z. Wang, M. Flagella, D. Wildes, J.A. Smith, M. Singh, Z. Wang, A.L. Gill, Discovery of Daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers, J. Med. Chem. 68 (2025) 6064–6083. https://doi.org/10.1021/acs.jmedchem.4c02314.
[8] J. Jiang, L. Jiang, B.J. Maldonato, Y. Wang, M. Holderfield, I. Aronchik, I.P. Winters, Z. Salman, C. Blaj, M. Menard, J. Brodbeck, Z. Chen, X. Wei, M.J. Rosen, Y. Gindin, B.J. Lee, J.W. Evans, S. Chang, Z. Wang, M. Singh, Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers, Cancer Discov. 14 (2024) 994–1017. https://doi.org/10.1158/2159-8290.CD-24-0027.
[9] J. Lokhandwala, T.B. Smalley, T.H. Tran, Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance, Front. Oncol. 14 (2024) 1394702. https://doi.org/10.3389/fonc.2024.1394702.
[10] A. Petzold, T. Steeb, A. Wessely, E.A.T. Koch, J. Vera, C. Berking, M.V. Heppt, Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment, Cancer Treat. Rev. 115 (2023) 102543. https://doi.org/10.1016/j.ctrv.2023.102543.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
